ad35.cs.01
Vaccineexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00371189)
Timeline
Indications
Mechanism of action
- Plasmodium malariaeImmunity, active
Plasmodium malariae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ad35.cs.01
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01366534 | Phase 2 | Aug 10, 2011 | Crucell, GlaxoSmithKline, PATH |
| NCT01397227 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2011 | Crucell, PATH, University of Washington |
| NCT01018459 | Phase 1 | Apr 1, 2010 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00371189 | Phase 1 | Jan 1, 2007 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Crucell | For profit | 2 | 1 | 1 | 2011 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2007 |
| PATH | Academic/Hospital | 2 | 0 | 1 | 2011 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2011 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2011 |
5 organizations
Page 1 / 1